UNICORN Challenges Immunotherapy Resistance in MSS Colon Cancer
Most Oral Blood Cancer Prescriptions Face Insurance Rejection or Cost Barriers, US Study Finds
SLACOM Session at LGCW: Why Breast and Cervical Cancer Prevention Is Failing, and How to Fix It
DREAMM-3 Final Results: Belantamab Mafodotin Extends Response Duration Without a Survival Gain in RRMM
Henry Fung: The Evolving Role of Elranatamab in Multiple Myeloma Treatment
SABCS 2026: The Top 10 Breast Cancer Studies to Watch for Potential Practice-Changing Results
Humaid Al-Shamsi: Burjeel Cancer Institute is The First Specialized Oncology Institute Worldwide to Achieve Three ESMO Designated Centre Recognitions
Matthias Preusser: Can Re-Irradiation Improve Survival in Patients with Recurrent Glioblastoma?
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
